RNF168 and cancer: Here, we report that RNF168 interacts with TOP2α to mediate its polyubiquitylation, and we further show that RNF168 deficiency confers resistance to ICRF-193, a TOP2 catalytic inhibitor, and etoposide (VP-16), a TOP2 poison and cytotoxic anti-cancer drug.